In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How And Why Genzyme And Alnylam Expanded Their Alliance

Executive Summary

Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher sealed the deal.

Advertisement

Related Content

Biopharma Dealmaking Quarterly Statistics, Q1 2014
Financings Of The Fortnight And The Never-Ending Venture Round
Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results
Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates
The Alnylam Turnaround: What Changed Investors’ Minds?
Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel